Serdar YILMAZ, Gülnur TOKUÇ, Sedat ÖKTEM, Nadir GİRİT

Astımlı çocuklarda inhale budesonid tedavisinin kemik dansitesi üzerine etkisi

Amaç: Astımlı çocuklarda inhale budesonid'in kemik dansitesi ve kemik metabolizması üzerine olan etkisini değerlendirmek. Gereç ve Yöntem: Prospektif çalışmamıza, polikliniğimizde astım tanısı ile izlenen 5-14 yaşlar arasındaki çocuklardan 126'sı dahil edildi. Hastalar 6 aydan uzun süre inhale budesonid alan 86 astımlı çocuk (Grup I); ve inhale steroid kullanmayan 40 astımlı çocuk (Grup II) olarak 2 gruba ayrıldı. Hastaların serum Ca, P, ALP ve kemik dansitesi ölçüldü. Bulgular: Çalışılan 2 grubun serum kalsiyum değerleri sırasıyla 9.20.7; 9.70.5 mg/dl, fosfor değerleri 4.21.1; 4.60.8 mg/dl, alkalen fosfataz değerleri 415108; 402112 U/L, kemik dansite değerleri 0.89 0.09; 0.88 0.07 g/cm2 idi. İki grup arasında istatistiksel bir fark saptanmadı. Sonuç: Çalışmamızda ortalama 256102 mcg/gün ve 17.811 ay süre ile kullanılan budesonidin kemik dansitesi üzerine olumsuz etkisi saptanmadı.

Anahtar Kelimeler:

Budesonid, Kemik yoğunluğu, Astım, Çocuk, İleriye dönük çalışma

Effect of inhaled budesonide treatment on bone density in children with asthma

Objective: To asses the effect of inhaled budesonide on the bone density and bone metabolism in children with asthma. Material and Methods: Prospective study was conducted in 126 children with asthma aged 5 to 14 years, selected from the pediatric outpatient clinic. Two study group were assembled: 86 asthmatic children treated with inhaled budesonide for over 6 months (Group I); and 40 asthmatic children not treated with inhaled corticosteroids (Group II). Serum Ca, P, ALP and bone density was measured. Results: In these two groups studied (I and II) calcium serum levels were 9.20.7; 9.70.5 mg/dl, respectively; phosphorus levels were 4.21.1; 4.60.8 mg/dl, alkaline phosphatase levels were 415108; 402112 U/L, bone density levels were 0.89 0.09; 0.88 0.07 g/cm2, respectively. No statistically significant differences were observed between the two groups. Conclusion: There is no evidence in our study that inhaled budesonide mean 256102 mcg/day and 17.8±11 month duration has an adverse effect on bone density.

Keywords:

Budesonide, Bone Density, Asthma, Child, Prospective Studies,

PDF

___

1.König P, Hillman LCervente CI. Bone metabolism in children with asthma treated with inhaled beclamethasone dipropionate. J Pediatr 1993; 122:219-26
2.Boulet LP, Giguera MC, et al. Effects of long term use of high dose inhaled steroids on bone density and calcium metabolism. J Allergy Clin Immun 1994; 94:796-803
3.Hanania NA, Chapman KR, et al. Dose related decrease in bone density among asthmatic patients treated with inhaled corticosteroids. J Allergy Clin Immun 1996; 96:571-79
4.Baraldi E, Bollini MC, et al. Effects of beclamethasone dipropionate on bone mineral content assessed by X-ray densitometry in asthmatic children; a longitudinal evaluation. Eur Respir J 1994; 7:710-4
5.Sorva R, Turpelnen M, et al. Effects of inhaled budesonide on serum markers of bone metabolism in children with asthma. J Allergy Clin Immun 1992; 90:808-15
6.Kannisto S, Korppi M, Arikoski P, et al
Biochemical markers of bone metabolism in relation to adrenocortical and growth suppression during the initiation phase of inhaled steroid therapy
Pediatr Res 2002; 52:258-62
7.Plebani M, Bernardi D, et al. New and traditional serum markers of bone metabolism. Clin Biochem 1996; 29:67-72
8.Hodkinson A, Thomson T. Measurement of fasting urinary hydroxyproline /creatinine ratio in normal adults and its variation with age and sex. J Clin Pathol 1982; 35:807-11
9.Kaniş JA. Assesment of bone mass and osteoporosis. Osteoporosis. Revised edition. London 1995; 114-147
10.Blake GM, Fogelman I. Bone Densitometry, X- ray and Quantitative Ultrasound. In: Geusens P (ed). Osteoporosis in clinical practice. London 1998;41-48
11.Geusens P. Dual Energy X-ray Absorbtiometry in Daily Clinical Practice. In: Geusens P(ed). Osteoporosis in clinical practice. London 1998;59-65
12.Cooper C. Rational and clinical indications for bone density measurement. Osteopor Int Suppl 1996,2:56-8
13.Paoli VM, Gomez EM, Valeri E, Salinas R, Bellabarba GA. Effect ofbudesonide on bone density and metabolism in asthmatic children. Salud Publica Mex. 2000; 42(4): 309-14
14.Biochemical markers of bone metabolism and calciuria with inhaled budesonide therapy. Akil I, Yüksel H, Urk V, Var A, Onur E. Pediatr Nephrol
2004; 19(5):511-5
15.Agertoft L, Pedersen S. Bone mineral density in children with treatmen asthma receiving long term with inhaled budesonide. Am J Respir Crit Care 1998; 157:178-183
16.Russel JH, fanice AD, James P, et al
Crosssectional study of bone density in asthmatic children. Pediatr Pulmonol 1995; 20:189-192
17.Bahçeciler NN, Sezgin G, Nursoy MA, Barlan IB, Basoran MM Inhaled corticosteroids and bone density of children with asthma. 2002;39(2):151-7
18.Altintas DU, Karakoc GB, Can S, Yılmaz M, Kendirli SG. The effects of long term use of inhaled corticosteroids on linear growth, adrenal function and bone mineral density in children
2005;33(4):204-9
19.Packe GE, Douglas JG, et al. Bone density in asthmatic patients taking high dose inhaled beclamethasone and intermittent sistemic steroids
Thorax 1992;47:414-7.